Efficacy and Safety of Ciclesonide Nasal Spray in Participants with Seasonal Allergic Rhinitis (SAR) in Russia

Study identifier:CIC-RR-001

ClinicalTrials.gov identifier:NCT02155881

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Phase III (Registration) Study to Assess the Efficacy and Safety of Ciclesonide Nasal Spray (Omnaris®) 200 mcg Once Daily in the Treatment of the Patients with Seasonal Allergic Rhinitis (SAR) in Russia

Medical condition

Seasonal Allergic Rhinitis

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide, Ciclesonide Placebo

Sex

All

Actual Enrollment

80

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2014
Primary Completion Date: 01 Oct 2014
Study Completion Date: 01 Nov 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria